- Earnings call transcript Q3 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning. My name is Colby and I will be your conference operator today. At this time, I would like to welcome everyone to the Third Quarter 2022 Seres Therapeutics, Inc. Earnings Conference Call. [Operator Instructions] Thank you. the to turn now will call Dr. over I Relations. Tanzi, Head Investor of Carlo

Carlo Tanzi

morning. Thank you and good

anticipated Our the X:XX be that status approval release for and on investigational company's first-in-class not business this press cash of launch website. potential and oral for including are and microbiome making SER-XXX, the indication update results XXXX morning results its to statements fact. section became forward-looking operations other and Investors financial for I'd and against The statements, available of potential be the may like we'll at the infection, can A.M. protect News time company's Eastern found third the SER-XXX therapeutic. quarter to you of to differ Actual fund historical which remind in materially. use therapeutics the

to today's uncertainties the our section statements risks that, We will Eric On on be made future Medical filings. these do Henn, are Arkowitz, Additionally, remarks, these prepared call joined Seres' pass disclaim also the obligation Officer; and Molke, SEC call so. I’ll I'm Scientific as views but may With David Factors the our Chief today's and to team recent President certain available Officer; of subject Risk update under CEO; any CFO; by management in of von with Lisa to Matthew Dr. Eric. Shaff, Chief today statements of discussed Dr. call members our Q&A. additional are only. represent statements the forward-looking we and which Any during

Eric Shaff

excellent microbiome approach. morning, good Carlo make you, and Seres our everyone. therapeutics continues advancing Thank progress to

has success. BLA FDA of lead priority were SER-XXX our review the very the to commercial and regulatory organization, by action announce agency therapeutic for difficile recently a has pleased XX, drive infection date SER-XXX, PDUFA of to for provided target been secure candidate an our top are the C. April recurrent that As We our and microbiome XXXX. priorities approval accepted

supported definitively high efficacy a managed, opportunity This III believe hospital favorable that procedures. a to transform approval condition that is SER-XXX is how that showed from avoids safety to burdensome Seres have that We important would represents a and as the are approved by recurrent of recurrent Phase the of patient to The microbiome of that program systems. and, SER-XXX, showing durable have SER-XXX provide develop filing route These costly SER-XXX medical serious the as SER-XXX CDI potential also far options beyond clear matured today. better burden diseases. profile new clinical believe We a and could an may microbiome oral reduced therapeutics administration medicine that by product limited modality. We FDA, multiple a a development launch Our additional as outcomes validation, CDI. complemented believe is for for resulting well have in attractive has BLA patient-friendly other life-threatening if coupled medicines with profile. a winning this suffering those new patients by represent facing levels profile

we believe recurrent cases planning per is substantial, will detailed across patient the SER-XXX's webcast data our opportunity to our at to Health Science X. are experiencing that Nestle information payers team and preparations this And supports and eagerly a provide hosting market that plan access. our this a clinical preparing support recurrent make Alongside SER-XXX approval FDA in is clinical We upcoming group, about and event. advancing those milestone therapeutics recurrence. launch nearly and be XXX,XXX excellent after Company, the immune benefit on additional with our an of for first collaborator, patient potential soon team with The efforts for market progress broad broad launch commercial educational our continues physicians year. investor including of December CDI CDI event we opportunity We

As recognize importance a capabilities has Seres of manufacturing founding have potential point strong also launch, of in emphasis the towards produced approval and over decade this we ago. we of the and approval. a drug move for commercial a FDA We since now company's been product anticipation

product manufacturing are external with working addition ensure met In also needs following increasing capabilities, closely to internal launch patient partners to longer-term Seres' are supply. manufacturing while we

for Our anticipated covering objective future market prepare potential uptake demand is to scenarios.

is our substantial also microbiome have therapeutic to continue Phase on our to gastrointestinal bloodstream patients This infections, where believe program, our microbiome infections we therapeutic and SER-XXX priority, of Ib receiving reduce GvHD While designed includes SER-XXX promise. we could the approach in execute allo-HSCT. additional a opportunities incidence

well novel working developing are solutions additional discovering of and may continue well research, that We also Seres Supported other candidates patient on has provide preclinical and positioned a at-risk microbiome therapeutic to are over for by decade a platform technologies differentiated of we medicines. groups. established

settings of clinical the to applying are approach disease. that, I'll With call more to research in in infection over gastrointestinal We diseases, to treat microbiome broadly unmet medical our and Lisa efforts high our where the in for a support needs both recently addition our now discuss to data. presented role some pass of

Lisa von Moltke

speaks The significance and New the results year. results. to England is III III Association of This highly of in month, additional the Phase of the Last this Journal manuscript of study SER-XXX Phase results Medicine published Phase we Journal earlier initial October pleased followed the the in data the of publication were remarkable two Medical American in SER-XXX the the have XX journals the Eric. these III publication in it to very Thanks, ECOS-X-X respected issue.

presented American recurrent ECOS-X-X as two additional that treatment. apparent data at College the the IDWeek prevention study. of meeting. XXXX SER-XXX The showed recently was and SER-XXX of Gastroenterology annual new post We results also recent as We the CDI highlighted from weeks presentations early

with affairs were our to able clinical durable to numerous was with doctors that are In interact responses gastroenterologists recurrent CDI. and be seen infectious treating At meeting, weeks. shown XX sustained addition, colleagues the medical disease actively through clinical the benefit

BLA FDA provided target SER-XXX breakthrough an that us that remind date accepted therapy designation BLA mentioned, I'll filing you obtained the the for expedited PDUFA we review we action PDUFA SER-XXX and XX. our As are priority has previously we the had reflects of a with of and April review pleased very obtained for date Eric submission.

The the currently meeting continue application. We they to not to FDA engage submission. with are committee to the indicated they closely that as an the hold advisory planning discuss review FDA

submission of product discuss We pass I are confident in in of additional BLA the and are eagerly preparing next year. now decision the call data, SER-XXX and to the April an Matt quality anticipated the will we clinical efforts. approval SER-XXX for R&D to

Matthew Henn

Lisa. you, Thank

graft our interest infections investigational receiving a SER-XXX cell therapeutics with Beyond - Seres, infection for including to SER-XXX The infections, SER-XXX, infections very infections, SER-XXX this high which microbiome utility. address believe conducted allogeneic SER-XXX, versus potential of we including allogeneic The hematologic both area by undergoing in in part to bacterial Ib malignancies including in disease. is we approach drug of to individuals microbiome at engraftment the area stem protection evaluate resistant where issues. transplant. risk therapeutic believe and in an franchise, infections treatment disease address patients advanced pipeline next medical such developing vancomycin widespread bacteria managing along cell provide is SER-XXX, may that including study particular with challenge microbiome the we patients transplant an novel the are expanding are host serious stem our targeted well leukemia. antimicrobial-resistant has Phase designed candidate host most carbapenem-resistant individuals graft pathogens that antimicrobial is tracts. of therapeutic program The and pharmacology, is to as being of versus as by gastrointestinal And as for as and study safety

of data being evaluate conducting Cohort tract In reduction next infections end on study's clinical rates addition, and anticipate meeting versus the outcomes, are We the graft abundance year. data data monitoring pathogens to host X the preplanned bacterial with safety the board disease. gastrointestinal bloodstream SER-XXX by the review collected the to of of in and including acute in

we favorable would addition, early infections. as from in as of Phase manage bacterial immunocompromised microbiome engraftment, such SER-XXX patients, In and approach to Cohort X, the important milestone plan therapeutics Demonstrating highly resistant be a the data safety an Ib study, antimicrobial to initial and pharmacological in species announce safety expansion those XXXX. novel drug and including for bacterial

for Looking enabled is translational therapeutics microbiome preclinical infections. strong the patients. blood an cancer therapeutic compromised patient neutropenia, ahead cirrhosis infection candidates. Significant microbiome potential and in prevent multiple platform our that and risk therapeutics exist to to groups, has MBTX clinical those that believe supporting of pipeline as expansion, patients in high of evidence the solid Seres' development with reverse at data integrated platform novel such stream discovery organ transplant opportunities medically and we provides

Our approach the data leverages customized therapeutics. and sets preclinical discovery models of data for and combined assays from a development broad clinical range in-human with microbiome of

and our progress year. infection anticipate We slow about in antimicrobial are targeting pandemic We making infections. preclinical information providing combating coming the additional programs of significant advancing candidates the resistant next more clinical

leverage With clinical of potential David turn the in call to inflammatory overview provide to microbiome and that, addition, to of immune-mediated now an disease data In advance reverse financials. I’ll unique translational platforms settings. of continue our and our understanding we our therapeutics the sets to

David Arkowitz

bring offering, the of to million. balance financials cash quarter included a in in we third meaningfully equity approximately registered morning, cash, Thanks, press Seres enables reiterate Matt. This effectively figures marketable to so more company to the our securities. our $XXX ended details capital sheet resulting in of third on therapeutics In issued here. the proceeds this strengthens need. position are completed won't earlier the all deliver July, XXXX in direct The patients with of our and gross release $XXX microbiome million equivalents and I quarter

include on Regarding Bacthera the launch SER-XXX to and conjunction our our our we a critical well continuing be efforts readiness operations SER-XXX activities. Aimmune, for both number collaboration; and supply, supply related near through Recipharm, manufacturing as with continuing continue which and of accelerating with and in ramp focused partner as product internally commercial resources activities up longer-term term, to increasing over

on to We build further enhance a with infection and also protection upon capabilities. and continue our opportunities and to and platforms our invest expand pipeline focus advance

we to well sustainable turn programs research resourced to platforms have I'll to the our also prepare Eric. commercialization and advance and drive to we now company expenses to these across preclinical as growth but of be we our summary, at we the already increase a organization. and a activities, rate our in much high In result of expect of where expanded to continue advantages. and while to moderating quarters deploying call our As differentiated ongoing have development the believe for SER-XXX resources continues coming proprietary the value-generating capabilities back priority

Eric Shaff

a as Thank you, have a SER-XXX microbiome bring approved by therapeutic differentiated FDA. for David. We to now if patients view clear the CDI, to recurrent

succeed the X, about Our we and team, event. taking to few commercial to to Seres Aimmune, I December transforming so with tune weeks, stage opportunity commercial that in thereby necessary along were forward able organization. with you information launch, strong on with that SER-XXX look a into We is much more a a providing why see hope steps into

that, to data year, with program, are to the for the the candidates of support information inflection highly programs I'd advancing their microbiome advancing to is call our providing coming thanking team to need efficiently work. talented key our progress, In to to of also groundbreaking Seres questions. while to about science promising therapeutic team more addition these by in intend lead in this new like look We responsible let's also patients In medicines. move programs. therapeutic you forward and a future pushing we close these for forward continue hard is dedicated with open that points. candidates. we pipeline to up Operator, forward It

Operator

question comes from of from Howerton Chris first line Your the Instructions] [Operator Jefferies.

Unidentified Analyst

produce brought This progress scheduled is for from readily play visit Chris. terms morning. [indiscernible] into in CMC Has production, Thank have launch? What FDA Good couple a is and any Bacthera up for to preparations? us. partnership you commercial you the do upon of And first the the site And batch the questions the supply? how issues? very commercialization will much. the A your of launch and infrastructure

Eric Shaff

Sure.

thanks the questions. for So,

and can about me and asking Let Dave next by questions. preparations the on to start commercial our I comment talk two Terry then

Teresa Young

Eric. Thanks, Sure.

SER-XXX saying start have a months, and finally we're excited Let to that by to date not can me bring PDUFA know in so patients we years.

also conversations media infection. we're speed in which educate that relationships ramped example of arrangement the spend a a with root mind, our remind we've microbiome robust Week products. the in need that open importance the mentioned the And fact, of we of DDW education had American Lisa for kept deployed I've say foundational again, And restoration fully reach elevated, both the early spend this recurrences and the SER-XXX - disease continuing because as Gastroenterology microbiome payers broadly on, in-line They but able ID the efforts We're to of our College field right And just phase. and stakeholders through group cause for beyond that this focus all referenced, everyone these May of preexisting So recent convention team co-commercialization significantly I'll doors with their we the brings. an most benefits operational our is with of on relatively our in spring, deployment have the is Nestle with we the prelaunch restoration to Nestle I'll largest that team audience of leverage to can HCP and in last engaging play. And payer alongside convention. a conferences great GI existing to and month. the that, just key were previously the role that and

continue finally, the and profile. highly space perhaps to this strength bringing. as we reception we data and pivotal the audience approach positive So is engage of the of need unmet recognition the the innovative SER-XXX broadly, no of more in given surprise we're our this hear And

back to on it over Eric, So comment you I’ll CMC. Dave, and turn to

Eric Shaff

close first question, physicians the both to ID GIs ACG. spent and just mean, IDWeek out having at I with Terry. Thanks, time Yes. and

in I think to patients important have that that there the of important a particular, was that we was it's note just excitement thought And profile the note. SER-XXX with additional around to idea palpable options. having we

for we the FDA second FDA hear to visits to we very allows the us were into question: are reallocate activities, been those not of blow that they the preparing which to for an down by site would that I specifics AdCom say, inspections for were terms I haven't On will too. will precommercial be pleased blow that that to including -- resources opportunities we additional thrilled There historically, continue in our different have details. of visits, and gotten continue say we double some planning currently to time. from and on to

comment ask commercial quickly can the we stand. of terms I In production, maybe on where Dave to just

David Arkowitz

Sure, absolutely. question. Thanks for the

commercial we supply, Eric launch our on earlier. year. manufacturing further internally both with been next have support partner supply to external able and we So are to and Recipharm, mentioned as That's the subsequent and be ongoing past track

asked required market is stated additional in capacity be later meet what That and the we've and years upside past, in as the Bacthera to not expect launch. we intended You for expansion. Bacthera about to is

Unidentified Analyst

Excellent. for Thank much you answers. Appreciate very your it.

Operator

comes Cowen. question from next from Peyton Your the Bohnsack of line

Peyton Bohnsack

I taking from that was for XX Will any on BLA monitoring X that only portion have Peyton safety our Is already was include all is from Congratulations for patients? will efficacy And readout from the it you include This the trial? questions. safety begin mentioned the thanks SER-XXX data upcoming option enrolling program, data begun the and initial there awesome the option enrolling before the the cohort? the the maybe Cohort then Joe. to guess option review? previously, data XX-week data the open-label to be after available quarter submission open on that this Or and on label. there of

Eric Shaff

you Yes, the thanks questions. for Peyton. Good morning and

clinical Maybe side including is question Cohort, side. Matt microbiome on what and question I the this we with to see efficacy ask comment comment I can to expecting think the Lisa on to data. are the the of first

Lisa von Moltke

Yes.

Board. review X. and safety make meeting Data safe mission So appropriate any it the is the its safety whether such, planned to charter Safety a of is Monitoring Cohort into as events proceed at decision on and a And it's is to to look

looking infection to that endpoints cetera. open planned would we if particular this study, after should will, mixing, safety et X I you we of rates, efficacy Cohort some endpoints are that. So, at be because have in and immediately say

So get database. live there it we some be will will still information clinical but a

So And is It populations this in this mind. that really recall as to also with immunocompromised. we our safety for our the other comprehensive that's regard to that look note; similarly gives not keep X. us for are additional Cohort first approaches at really that just And have into in immunocompromised population. important important really an other planning

Matthew Henn

Peyton. Good morning,

for trials company to and time reverse be long discovery empower our development Seres and company. our translationally And know, the is followed designed translational you You've rich as a are a efforts. to data-driven

of Cohort focused about to talked information we earlier safety drug be today, focus the that the pharmacology. Lisa drug data on And we'll So preliminary and noted evaluate on. provide as that's X, is and

engraftment So disease-relevant and data other XXX bacteria such the in of as potentially some parameters.

we'll and We data haven't I in a out find company, a getting that key that have specific release as guided XXXX. findings of to we the But there. releasing trials history from we think

Peyton Bohnsack

you All quarter. right. much on congrats so guys the Thank and

Operator

question next of Piper Tenthoff Sandler. Ted line comes Your the from from

Ted Tenthoff

Thank questions you. are XXX discuss bit partnership today so collaborative operating we a that forward loss in everybody we recognized of event being Congrats correct? but weeks the expenses, the get that the that a just and My the morning. maybe that could currently it to call annual profit couple in figured in are attributable in Good I are can The line. Great. line profit, PDUFA expenses Tier housekeeping on little on to are of here. looking

Eric Shaff

David?

David Arkowitz

Yes.

a basis, pre-approval So on are Ted. we prelaunch

of that amount loss of gets expenses incur to commercial and loss million covering then profit expenses. incurs what's us the piece that that million, $X related about up in you're and activities commercial see are ourselves the $X We going think Aimmune up we million to expenses XXX% preapproval to If additional showing as those those $X profit collaboration collaboration. in

Ted Tenthoff

the out. do that line? will So -- remain area? really super Got it's line year, profit then exciting. SER-XXX in up Or a has And collaboration, next a the the to with as line launch profit it Or that then you will in achieve in you it to would revenue question negative you. as be float OpEx

David Arkowitz

Yes.

I post-approval which to ahead is: with But exact And collaboration external of accounting. of with auditors additional out XX%. disclosure think will figure auditors P&L, that. And or breakout. about to exact as about be working, of the the in to down our our that net there be collaboration that may working that's the XX% said, may us. So is of single be the a we're captured nail loss we way that a we get line profit think or It of that effect

Ted Tenthoff

enough. to looking the We'll to and look couple and just forward event stay fair in tuned weeks. that forward a of Okay,

David Arkowitz

questions. Thanks for the

Operator

from Breidenbach Your question the next Mark line from Oppenheimer. comes of

Mark Breidenbach

going I field et on a an was these more I think NSLs, already be about to onboarded And employees? a support reps, probably of number regulatory the you force sales cetera? could but date? of to remind launch? been of the And or we’ll how advent hoping hear are bit expect the X these the December before size this overall the Aimmune decision have deploy you employees early PDUFA The in Seres many of little on to us

Eric Shaff

Terry I first can ask the on Lisa I side. got can question MSL of made sales the comment think force think and of but maybe to and Mark, on you that couple we we gist missed the Yes. sizing comments I comment maybe the

Teresa Young

Sure.

depth our event. and management be will, the your as we X additional on we providing Mark, So Aimmune guests point, have will to December

you calendar. C.diff you invite that I HCPs This will that put greatest what in for we can your is with the patients. infection. be is reach that definitely and tell today a to potential I general, recurrent to But seeking So, the attend in treating gut

to of that gastroenterology specialties. specialists patients have disease the no highest it's surprise other relative So and infectious these concentration

for that deployed may currently a have Nestle also gastroenterology their recall calling today team [ph]. field You sales product on

the new the planning As top also building expertise teams Aimmune in to effective at post-COVID we side. products. line on at this and ways world. fully communicating launch forward staff normal, Aimmune it hospitals, because leveraging field infectious to disease to they We’ll of expertise And and we point physicians this in exploring efficient prescribers our have has be this are include significant look upon this there and sort of with

and them, you, to to we So model learning look forward Eric. to our come the more Back finalizing from Xth. on go-to-market

Eric Shaff

the on Yes. Lisa, do you want MSL to comment strategy?

Lisa von Moltke

Yes.

quite large active conferences across the GI fully been with Also, have and and the KOLs. with time meeting practices at for now MSLs meeting but ID So not been they've only deployed country. some

group So the I for and been has the think publication schedule between launch. med active that group affairs and maintained, has active that affairs very extremely ready

Mark Breidenbach

Okay.

in if make on need capacity. bunch necessarily of manufacturing So question like per And year, understanding future, of for me in of near-term it sounds to doses one additional just correctly. you don't the Have what I'm for sort SER-XXX? a is hires other terms disclosed the current capacity is you

Eric Shaff

first question. to yes. Mark, the out Yes, close The answer just is

as mentioned, until Lisa been of and some of have MSLs and field we existing it kind in the we approval. the Part not time. could with capacity build attraction Aimmune wait that an that on with the idle to leverage sat for infrastructure working ourselves GI turned have and was of the Nestle As it

maybe where there. feel we piece. the So are on you can about commercial comment we good David,

David Arkowitz

Yes.

about. guided things So you specifics there we've could I couple don't believe I but of remind a any are just

up if hundreds, ahead that the product. this we're and thing a that key staying more, our past, out in lined of one, capacity for other the amount the single able product closely in said donor So Aimmune terms to differentiates we're that from not we're doses of as is And that. get tell with have of we forecast can with you I comfortable and we've

oral that purified So scalability of this given we medication. it have think really of as highly an product nature lot the a spore we differentiates

Mark Breidenbach

progress. Congrats, super again, Okay, helpful. the on

David Arkowitz

Thanks for Mark. questions, the

Operator

the from Canaccord. from Your of John Newman next comes question line

John Newman

reimbursement. on had launched congrats I is SER-XXX prescribed the is progress when about curious the regarding and product with a do questions being I’m What and question prescribed, my foresee treatment? SER-XXX. is DRG you eventually on taking outpatient this for Thanks because asking payment method the part as possible, an could included or being is some wondering of you that in I’m if as And of if get a the around hospitals. I’m reason considered

can there. about if little the talk you a dynamics bit curious Just

Eric Shaff

Good morning, can thank the you a Maybe Terry John, outpatient question. specifically nature our for the invite about journey of patient bit little I expectations. the and talk to

Teresa Young

course The thanks Of vast of majority these John, for setting. the outpatient will patients question. and be treated the in

patients vancomycin in abrupt. hospital they which upon and And and quite works it going many they DRGs important And toxin benefit will then because initially so you symptoms inpatient are it’s the to address note So so they drug that… ill, And works are so benefit the that the be and it’s that through acute the the prescribed governed journey. the quickly. is therefore, the admission do versus patient by Eric referenced. for to of go that outpatient the these reason referenced product

becomes So the of vancomycin, to improved, you second finish then or markedly patient hospital SER-XXX. know, completion they their upon from vancomycin And outpatient that as the symptom-free start it’s regimen. would they’re discharged

trials patients the the treated outpatient through gives entirely Back you, Eric. SER-XXX that saw the outpatient. you There’s also our in actually these traveling of significant into a number why behind that benefit. and patients some primarily are we in So drug insight to

Eric Shaff

John, provides our that perspective. I think

John Newman

you. Thank Yes.

Operator

Chris of Sachs. line from the Goldman from comes question Shibutani next Your

Unidentified Analyst

our Stephen on for Thanks question. for is This Chris. taking

infection planned we in? protection Just noticed is initiating and Can just will you strategy XXXX. if then, partner could commentary in of SER-XXX wondering about if we on you latest later that your what this comment subject for Investor expect if December. release the at that you. how program if your Aimmune for clinical thoughts And upcoming development program are pricing around stage or an the should this And years? in in Day any on be to Thank approved? in have provide XXXX we studies wondering We’re thinking you expect potentially additional press clinical should

Eric Shaff

for a Yes, pricing maybe Terry I as we on, or about expectations weeks. can to start Stephen, thanks by the in Maybe questions. to general, asking talk what in comment strategy will set few

Teresa Young

months time severely the while to work Aimmune ill need with desperately the the to we the over and patients in patient who better take of balance partners Well, in the our access a Nestle bringing the we really innovation of to representing option. Sure. achieve division continue ensuring value that right have for we're

You C. area Eric, may diff year. infection This December patient in is of continuing health pricing potentially cost system. cost our a us high the work this X you. recall consider our but costing additional $XX,XXX the on to option to on premium care thinking in the gives be we'll Each to average back an high event. and provide depth

Eric Shaff

engine And and capabilities C. point where we infection a knowledge into starts priority regulatory we start at incredibly are bringing from we certainly portfolio. adjacencies year same the can preparing It made but XXX feel that insights excited our for Yes, then it we and XXX. question with next doesn’t thought I to the be Matt discovery maybe our SER-XXX of Stephen, what’s diff, were in into the end with invite second our of launch. a time, the to success. getting and of our decision approval company, area continues But But could last that with to and and to we comment. infection probability improve about course, as as

approach be think We are we microbiome can and that continue And that Matt comment to of further of areas on a could that. need excited ahead relevant maybe us. the be unmet about

Matthew Henn

capabilities We've these been considerable space. a move clinic. our importantly, pathogens. multiple also other a able to make where And well, opportunities very are we're portfolio is we able based from because the other move as quickly with rapidly and designing the towards kinds terms platform think commercial strong different infection we a We've handful SER-XXX I new in disease moving of we And that, of quickly to asset of to a of the rapidly then, both in areas. manufacturing for for learn in reason development the about broad And strong drugs, space. therapeutic proof bacterial been And been the have indications as data well which infection clinical feasibility patients out to and candidates mine concept of with to lead those though, feasibility map get have of can those as data. a different on

solid So in coming readouts as immunocompromised the we see XXX couple safety which in populations I out transplant, clinical the program programs of an as And well noted speaks anticipating in as to others on. of earlier, have additional a cirrhosis, real that of opportunity we are next patient importance year. near again organ working we the And term. we cancer launching active are neutropenia, a

Unidentified Analyst

Thanks appreciate for color. it. the I

Eric Shaff

for Stephen. Thanks question, the

Operator

no time. turn call further over management closing at back the this now remarks. to questions for are I will There

Eric Shaff

all great deal our Well, going thank for X time at attention thanks your you of updating forward you, look to A quarter progress important and on operator morning. this event. progress, and and December including we this our forward

So this for much very Thanks with call. again can attention. that, conclude operator, your we

Operator

today's concludes call. conference This

You disconnect. may now

Seres Therapeutics (MCRB) 2 Nov 222022 Q3 Earnings call transcript